- Home
- APLT vs CGTX Comparison
APLT vs CGTX Comparison
Compare APLT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CGTX
- Stock Information
- Founded
- APLT 2016
- CGTX 2007
- Country
- APLT United States
- CGTX United States
- Employees
- APLT N/A
- CGTX N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- CGTX Health Care
- Exchange
- APLT Nasdaq
- CGTX Nasdaq
- Market Cap
- APLT 63.6M
- CGTX 53.4M
- IPO Year
- APLT 2019
- CGTX 2021
- Fundamental
- Price
- APLT $0.42
- CGTX $2.17
- Analyst Decision
- APLT Buy
- CGTX Strong Buy
- Analyst Count
- APLT 6
- CGTX 3
- Target Price
- APLT $6.10
- CGTX $2.83
- AVG Volume (30 Days)
- APLT 883.6K
- CGTX 8.0M
- Earning Date
- APLT 11-06-2025
- CGTX 11-12-2025
- Dividend Yield
- APLT N/A
- CGTX N/A
- EPS Growth
- APLT N/A
- CGTX N/A
- EPS
- APLT N/A
- CGTX N/A
- Revenue
- APLT $121,000.00
- CGTX N/A
- Revenue This Year
- APLT N/A
- CGTX N/A
- Revenue Next Year
- APLT $5,931.24
- CGTX N/A
- P/E Ratio
- APLT N/A
- CGTX N/A
- Revenue Growth
- APLT N/A
- CGTX N/A
- 52 Week Low
- APLT $0.30
- CGTX $0.22
- 52 Week High
- APLT $10.62
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- APLT 38.92
- CGTX 52.79
- Support Level
- APLT $0.43
- CGTX $2.33
- Resistance Level
- APLT $0.46
- CGTX $2.60
- Average True Range (ATR)
- APLT 0.03
- CGTX 0.34
- MACD
- APLT -0.01
- CGTX -0.09
- Stochastic Oscillator
- APLT 0.35
- CGTX 15.31
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.